After reconstitution, refrigerate at 2-8 degrees Celsius and use within 2-4 weeks
Early in a bulking phase when you need maximum food intake to support rapid strength gains, a lower dose might be preferable
A STEP 1 subanalysis did show that participants taking 1 mg of semaglutide lost an average of roughly 16% of their body weight over 64 weeks, which was close to the results at 2.4 mg
You may be randomized to placebo a 50% chance in most trials
News provided by Novo Nordisk Jul 01, 2026, 07:00 ET Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity

And for every one of those patients, a competent, qualified nutritional counselor can dramatically lower the impact of side effects